The disclosure provides for pathogenic biomarkers and serum extracellular vesicular biomarkers that are associated with vascular anomalies and malformation of endothelial cells, and uses thereof, including for diagnosis, prognosis and therapy.

The purpose of the present invention is to develop a method for screening drugs having the effect of increasing skin barrier function in in vitro studies and to evaluate barrier function in the skin. Candidate drugs can be screened by using the activity and/or expression level of serine racemase as an indicator.

A method can be used for analyzing digital images of skin lesions. The images include pixels distributed over a lesion area. Sets of values including a first discrimination value indicative of a weighted average of the image pixels with weighing at the border of the lesion, a second discrimination value indicative of skewness and kurtosis of the distribution of the image pixels, a third discrimination value indicative of the ratio of symmetry and gray-level power of the distribution of the image pixels and calculated. A total additive score of the values in the sets of values is provided and compared with a total score threshold. The first, second and third discrimination values are compared with respective first, second and third discrimination threshold values. An output classification for the image analyzed is provided as a function of the results of the comparing.

A method can be used for analyzing digital images of skin lesions. The images include pixels distributed over a lesion area. Sets of values including a first discrimination value indicative of a weighted average of the image pixels with weighing at the border of the lesion, a second discrimination value indicative of skewness and kurtosis of the distribution of the image pixels, a third discrimination value indicative of the ratio of symmetry and gray-level power of the distribution of the image pixels and calculated. A total additive score of the values in the sets of values is provided and compared with a total score threshold. The first, second and third discrimination values are compared with respective first, second and third discrimination threshold values. An output classification for the image analyzed is provided as a function of the results of the comparing.

The subject matter of the present invention is in particular the use of an amino acid sequence of IDE, or of an analogue or fragment thereof, or of at least one nucleic acid sequence encoding this sequence, as a biomarker, or as an active agent, with regard to a dandruff condition of the scalp.

The present disclosure concerns an in-vitro method for the identification and analysis of proteins with a stem cell function, in which initially, at least one three-dimensional sweat gland equivalent with from about 500 to about 500000 sweat gland cells as well as a diameter of from about 100 to about 6000 m is provided and subsequently, proteins with a stem cell function in this equivalent are identified and analyzed. Preferably, in a further step c) of the method, the influence of test substances on the proteins previously identified in step b) is investigated. Because the three-dimensional sweat gland equivalents used in step a) comprise differently differentiated cells and emulate the in-vivo situation well, the measured data obtained with the in-vitro method as contemplated herein can readily be applied to the in-vivo situation.

The purpose of the present invention is to develop a method for screening drugs having the effect of increasing skin barrier function in in vitro studies and to evaluate barrier function in the skin. Candidate drugs can be screened by using the activity and/or expression level of serine racemase as an indicator.

The present invention address the problem of providing a transparent skin sample by removing epidermis via enzymatic treatment.

The invention relates to a method for determining a dosing scheme for the treatment of hereditary angioedema and/or the prevention of hereditary angioedema attacks with C1 esterase inhibitor to optimize treatment response in an individual patient. Accordingly, the present invention provides means for determining individual C1 esterase inhibitor dosing schemes that result in an optimal treatment/prevention outcome.

An object of the present disclosure is to provide a method and a system capable of extracting biomolecules simply and highly reproducibly by using skin tissue collected with a tape stripping method. The biomolecule extraction method according to the present disclosure is a method for extracting biomolecules contained in skin tissue by using an extraction reagent and a magnetic substance in an extraction container, and has the following features. That is, a tape that has collected the skin tissue is brought into contact with the extraction reagent and the magnetic substance, the magnetic substance in the extraction container is moved by magnetic force generated from a magnet provided outside the extraction container, and the biomolecules are extracted from the skin tissue into the extraction reagent by mechanical friction between the magnetic substance and the tape adhered with the skin tissue.